Pitfalls in cutaneous melanoma diagnosis and the need for new reliable markers
Files
(Published version)
Date
2022
Authors
Lam, G.T.
Prabhakaran, S.
Sorvina, A.
Martini, C.
Ung, B.S.Y.
Karageorgos, L.
Hickey, S.M.
Lazniewska, J.
Johnson, I.R.D.
Williams, D.B.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Molecular Diagnosis and Therapy, 2022; 27(1):49-60
Statement of Responsibility
Conference Name
Abstract
Cutaneous melanoma is one of the most aggressive forms of skin cancer, with the development of advanced stage disease resulting in a high rate of patient mortality. Accurate diagnosis of melanoma at an early stage is essential to improve patient outcomes, as this enables treatment before the cancer has metastasised. Histopathologic analysis is the current gold standard for melanoma diagnosis, but this can be subjective due to discordance in interpreting the morphological heterogeneity in melanoma and other skin lesions. Immunohistochemistry (IHC) is sometimes employed as an adjunct to conventional histology, but it remains occasionally difficult to distinguish some benign melanocytic lesions and melanoma.
Importantly, the complex morphology and lack of specific biomarkers that identify key elements of melanoma pathogenesis can make an accurate confirmation of diagnosis challenging. We review the diagnostic constraints of melanoma heterogeneity and discuss issues with interpreting routine histology and problems with current melanoma markers. Innovative approaches are required to find effective biomarkers to enhance patient management.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2022 The Author(s), under exclusive licence to Springer Nature Switzerland AG
Access Condition Notes: Accepted manuscript available after 1 January 2024